Trump Ditches New Negotiating Powers For Medicare Part D
Law360 (May 16, 2019, 9:57 PM EDT) -- The Trump administration on Thursday abandoned extra leeway for Medicare Part D plans to negotiate prices for prescription drugs that treat serious diseases, dealing a setback to its blueprint for making drugs more affordable.
In a final rule, the Centers for Medicare & Medicaid Services largely ditched proposals to let Medicare Part D insurers more aggressively restrict coverage in “protected classes” of drugs. The about-face, which followed lobbying attacks by drugmakers, is a defeat for one component of the administration’s blueprint on drug pricing, and it echoes a retreat by the Obama administration on proposed changes to the protected classes....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!